The FDA has not approved any of the six peptides at the center of this week’s news. As of October 2026, the FDA’s own scientists concluded there is insufficient data to prove they are safe and effective, according to the NBC News report. What changed is a policy from the Department of Health and Human Services, which says the FDA will not take legal action against compounding pharmacies that make BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
That is a non-enforcement policy, not an approval. Ars Technica reports that the rule “does not change the regulatory status of the peptide.” Below is what changed, what is approved, what is known about each peptide, the risks, and how to decide with a clinician.
What did the HHS policy change?
According to NBC News, HHS filed a notice on Wednesday, October 28, saying it would use “enforcement discretion” for these six peptides. In practice, compounding pharmacies can start offering them now, even though they are not on the FDA’s list of ingredients that compounding pharmacies are allowed to make.
The outlets describe the policy’s status differently. CBS News calls it a draft that is open to public comment from Friday through Nov. 13. Ars Technica reports that the rule, titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” was made available in the Federal Register with a final publication date of October 30. Search the Federal Register for that title to confirm the current status.
| What the policy says | What still holds |
|---|---|
| FDA will not take legal action against compounding pharmacies that make the six peptides (NBC News) | The six peptides are still not on the FDA’s compounding list (NBC News) |
| Pharmacies must certify identity and purity, and report side effects, which was not previously required (NBC News) | HHS says the policy “does not grant FDA approval or establish clinical safety and effectiveness” (CBS News) |
| Requires patient-specific prescriptions, traceable ingredients, quality testing and safety reporting (HHS spokesperson, CBS News) | The policy stays in place until the FDA finalizes a rule, and the FDA has not proposed one (CBS News) |
What is the FDA’s stance on peptides?
The FDA’s position has been cautious, and the July advisory vote did not change that. Here is the timeline the reports describe.
| When | What happened |
|---|---|
| 2023 | The FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded, citing risks of allergic reactions, kidney damage and tumor growth (AP report) |
| July 2026 | An FDA advisory panel narrowly voted to recommend adding six peptides to the bulk list. CBS News notes the vote “did not constitute FDA approval” and went against the FDA’s own scientists (NBC News, CBS News) |
| October 28, 2026 | HHS issued the enforcement policy for the six peptides (NBC News, CBS News) |
The AP report says most FDA scientific staff opposed the policy, according to six people familiar with its development who spoke on condition of anonymity. It also says FDA staff helped draft the HHS plan and pushed for safety measures. The AP report describes the HHS plan as a step back from the original goal of adding the peptides to the FDA’s list.
Critics and supporters disagree about the panel. NBC News reports that six of its new appointees had ties to the peptide industry. Ars Technica reports that Kennedy added eight new members to the 12-member committee and that at least six have ties to peptide-related businesses and clinics.
Which peptides are on the FDA-approved list?
The “list” in these reports is the FDA’s bulk drug substances list for compounding pharmacies, not a list of approved drugs. None of the six peptides is on it. Some peptides are approved drugs. CBS News reports that insulin is FDA approved as safe and effective, and that GLP-1 medications used for weight loss and diabetes also contain FDA-approved peptides. The AP report notes that drug companies have brought several peptides to market as medications, including mainstay treatments for diabetes and weight loss.
For the full list of approved drugs, check the FDA’s own drug listings or ask your pharmacist.
Which peptides is the FDA looking at right now?
The six peptides named in the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The AP video caption describes the July panel as recommending easing access to “6 out of 7 popular peptides.” The NBC, AP and CBS reports do not name the seventh. If you saw a list of seven, check the FDA’s July advisory meeting materials. The reports do not rank peptides, so there is no official “top 3” or “top 5” list.
What is BPC-157?
BPC-157 is one of the six peptides in the policy. NBC News reports that it has been promoted online as a treatment for everything from faster healing to younger-looking skin and a longer lifespan. Those are promotional claims. The FDA added it to its do-not-compound list in 2023 (AP report). AP also reports that Kennedy has described using it to treat a muscle injury.
What is known about each of the six peptides?
| Peptide | What the reports say |
|---|---|
| BPC-157 | Named in the policy. On the FDA’s 2023 do-not-compound list (AP report). Kennedy has described using it for a muscle injury (AP report). |
| TB-500 | Named in the policy. On the FDA’s 2023 do-not-compound list (AP report). |
| KPV | Named in the policy (CBS News, AP report). |
| Epitalon | Named in the policy (NBC News, CBS News). |
| MOTS-c | Named in the policy (NBC News, CBS News). |
| Semax | Named in the policy (NBC News, CBS News). |
What does the research show?
Very little human research. Ars Technica reports that there are “few to no studies involving humans that show either benefits or harms from the peptides.” The HHS argument, as Ars describes it, is that the safety concerns are mainly hypothetical or “inferential” and not based on observed harm in humans. Ars notes that this is partly because so few human studies exist. If you want to see what human trials of peptides have found, our peptides human studies (our research library) guide covers them.
What is the downside of taking peptides?
The reports point to several risks. The main ones are below.
| Risk | What the reports say |
|---|---|
| Serious side effects | The FDA cited allergic reactions, kidney damage and tumor growth when it listed peptides as not to be compounded in 2023 (AP report). The policy requires pharmacies to report side effects (NBC News). |
| Unknown contents | CBS News reports that a lab test of an experimental weight-loss peptide, retatrutide, bought from a Brooklyn bodega found the sample did not contain a peptide at all (CBS News). |
| Unregulated sources | Retailers sell peptides labeled “for research use only,” which NBC News describes as a legal workaround that lets them claim the products are not meant for humans (NBC News). |
| Little human data | Few or no human studies show benefits or harms (Ars Technica). |
Advocates for safer medicine go further. Shabbir Safdar of the Partnership for Safe Medicines said the enforcement policy and the coming rule change would expose Americans to “untested, dangerous substances” (NBC News). The Center for Science in the Public Interest says reports of harms will “continue to mount” (Ars Technica).
The FDA’s consumer page on hidden ingredients covers sexual enhancement and energy products, not peptides. It says such products are “likely to be contaminated with dangerous hidden ingredients” and are “sold online and in stores.” The page also advises talking to a health care professional “before buying or trying a new product for your health” (FDA’s page on hidden ingredients).
Can I legally buy peptides?
The policy describes licensed pharmacies and physicians making the six peptides under patient-specific prescriptions, according to CBS News and the HHS spokesperson it quotes. It is not an approval. Whether a particular purchase is lawful depends on where the product comes from and how it is made, so ask the pharmacy or prescriber how the policy’s requirements apply to you. This is information, not legal advice.
The policy is named “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” issued by HHS on October 28, 2026 (Ars Technica, NBC News). The FDA has not proposed a rule that would finalize it (CBS News).
What did RFK Jr. say, and who supports or opposes the policy?
Robert F. Kennedy Jr., the Health Secretary, has called himself a “big fan” of peptides (NBC News, AP report). Ars Technica reports he said he uses some of them. In his policy, Kennedy wrote that it “advances patient choice and freedom while appropriately protecting patient safety” (CBS News).
Supporters include Lee Rosebush, chair of the American Academy of Peptide Medicine, who thanked Kennedy for “taking a forward-thinking, evidence-based approach to the regulation of peptides” (Ars Technica). Opponents include Fred Mills of Americans for Safe and Effective Medicines, who said the rule “does not resolve problems with untested products, safety risks, questionable ingredients, or misleading claims” (Ars Technica).
Ars Technica reports that peptide sellers thanked Kennedy, President Trump, Calley Means and Joe Rogan. The Ars report does not say Joe Rogan takes any peptide.
Is there a most legit peptide company?
This page does not recommend a company or a place to buy. The NBC News report does not name any company as the most legitimate. Instead, use the policy’s own requirements as your checklist: an FDA-registered ingredient maker, a lab certificate for the raw ingredients, identity and purity testing, and a patient-specific prescription (CBS News, NBC News).
What are your options, side by side?
Prices are not in these reports. Prices and bundles change, so check today’s price directly with the pharmacy, prescriber or manufacturer.
| Option | Status as of October 2026 | What the evidence shows | Who it may suit |
|---|---|---|---|
| FDA-approved peptide medicines, such as insulin or GLP-1 medicines | Approved (CBS News) | CBS News reports insulin is FDA approved as safe and effective | People whose clinician prescribes one for a condition they have |
| The six peptides compounded under the HHS policy | Not approved; enforcement discretion (NBC News, CBS News) | FDA scientists concluded there is insufficient data to prove safety and effectiveness (NBC News); few or no human studies (Ars Technica) | Only a decision made with a clinician, under a patient-specific prescription (CBS News) |
| Peptides labeled “for research use only” | Not approved for people; described as a gray market (NBC News) | CBS News reports a sample tested without the peptide it was sold as | The reports do not recommend this option |
| Established treatments for your condition | Varies by condition | Depends on your condition and history | Decided with your clinician, who can compare them with the peptides above |
For dietary supplements and other complementary products, the NIDDK’s erectile dysfunction treatment page advises talking with your health care professional first, “for safety reasons” (NIDDK treatment guidance). If you are weighing supplements as an everyday route, our cordyceps for athletic performance guide covers the evidence and labels for one ingredient.
What should you bring, ask and track before deciding?
Bring:
- A full list of every medicine and supplement you take
- The condition you want to address and any past reactions
Ask:
- Is this one of the six peptides, and is it FDA approved?
- What human evidence exists for my situation?
- How does the pharmacy confirm identity and purity?
- Is the ingredient maker FDA-registered, and can I see the lab certificate?
- How and where are side effects reported?
- What is the total cost, and how does it compare with the other options?
Track:
- Any side effects, with dates and symptoms, to share with your clinician
- Your questions after each conversation
Compare the options the way our keeps vs hims guide does for ED options: side by side, with side effects and cost.
What is still unknown?
- Whether the policy will be finalized. CBS News reports the comment period runs through Nov. 13, and the FDA has not proposed a rule.
- Whether the policy’s final publication date was October 30, as Ars Technica reports, or whether it remains a draft, as CBS News reports.
- How much human evidence exists for each of the six peptides. The reports describe it as few or none.
By the Integrative Health Evidence Guide Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.